Laurus Labs Ltd

Laurus Labs Limited has announced its 21st Annual General Meeting (AGM) will be held on Thursday, July 2, 2026, at 3:00 p.m. IST via Video Conference (VC) / Other Audio-Visual Means (OAVM). The company is issuing a letter to shareholders without registered email addresses, providing a web-link to access the Integrated Annual Report for FY 2025-26. Shareholders are reminded of the mandatory requirement to update PAN, KYC, and nomination details with their Depository Participants to ensure uninterrupted payments, including dividends. A dedicated Senior Citizens Investor Cell is also available for assistance.

Laurus Labs Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report details the company's corporate identity, operations, employee data, and market reach. Key highlights include 100% turnover from Pharmaceuticals & Bio product development, manufacturing, and services, with 62.14% of turnover derived from exports. The company employs a total of 7,059 permanent employees and 6,773 workers, with a significant portion of its operations serving international markets across 61 countries. The BRSR report was prepared on a standalone basis and received limited assurance from M/s Deloitte Haskins & Sells LLP.

Laurus Labs Ltd has announced its 21st Annual General Meeting (AGM) scheduled for Thursday, July 2, 2026, at 3:00 PM IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM). Shareholders can access the Notice of the AGM and the Integrated Annual Report for the financial year 2025-26 on the company's website and NSDL's e-voting portal. The report provides a comprehensive overview of the company's performance, strategy, governance, and sustainability initiatives for FY 2025-26, highlighting investments in CDMO, Affordable Medicines, and FDF, alongside a focus on ESG principles and employee well-being.

Laurus Labs Ltd has announced its 21st Annual General Meeting (AGM) will be held on Thursday, July 2, 2026, at 3:00 p.m. IST via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The agenda includes the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, ratification of interim dividends totaling Re. 2.00 per equity share for FY 2025-26, re-appointment of directors Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava, and the appointment of Dr. Shekhar Chintamani Mande and Mrs. Sutapa Banerjee as Independent Directors for a term of five years.

Laurus Labs Ltd. has been included in the Dow Jones Best-in-Class (DJ BIC) World Index, recognizing the company's strong ESG performance and commitment to sustainable and ethical corporate governance. The DJBIC World Index ranks top-performing companies globally based on S&P Global CSA scores. Laurus Labs previously featured in the S&P Global Sustainability Yearbook 2026 with a CSA score of 81 out of 100, up from 71 the previous year.

Laurus Labs Ltd's Board of Directors, at their meeting on April 30, 2026, approved the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. Both appointments are for a term of five consecutive years, effective from July 02, 2026, and are subject to shareholder approval. Dr. Mande is a distinguished structural and computational biologist and former Director General of CSIR. Ms. Banerjee's profile was also annexed. The Board also noted the retirement of Mrs. Aruna Bhinge as an Independent Director, effective from the close of business hours on July 6, 2026, upon completion of her second term. The new appointees are confirmed to be unrelated to any existing directors or Key Managerial Personnel and are not debarred by any regulatory authority.

Laurus Labs' Board of Directors, at their meeting on April 30, 2026, approved several key decisions. The company will appoint Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 2, 2026. Concurrently, Mrs. Aruna Bhinge will retire as an Independent Director on July 6, 2026, after completing her second term. The Board also approved an investment of up to EURO 9.8 million in KRKA Pharma Private Limited, a joint venture, to fund its capex for a new manufacturing facility, maintaining the 51:49 shareholding ratio with KRKA d.d., Novo mesto. Additionally, the voluntary closure of Laurus Generics GmbH (Germany), a non-material step-down wholly-owned subsidiary with nil turnover, was approved, which is not expected to have a material financial impact.

Laurus Labs Ltd's Board of Directors approved the voluntary closure of Laurus Generics GmbH (Germany), a step-down wholly-owned subsidiary. The closure is subject to regulatory approvals in Germany. The company clarified that Laurus Generics GmbH is not a material subsidiary, reporting Nil turnover for the financial year ended March 31, 2026, and a negative net worth of Euro 1,053,091. The closure is not expected to have any material impact on Laurus Labs or its financial performance.

Laurus Labs' Board approved an investment of up to EURO 9.8 million in its joint venture, KRKA Pharma Private Limited. Co-venturer KRKA d.d., Novo mesto, Slovenia, will also invest approximately EURO 10.2 million. The existing 51:49 shareholding ratio between KRKA d.d. and Laurus Labs will remain unchanged. This strategic investment will fund KRKA's capital expenditure plan for setting up a new manufacturing facility. The transaction is classified as a related party transaction, conducted on an arm's length basis. KRKA Pharma, incorporated in April 2024, is in the pharmaceutical industry and reported a turnover of INR 10.47 million for 2025-26. The investment is expected to be completed in FY2026-27.

Laurus Labs Ltd's Board of Directors, at their meeting on April 30, 2026, approved significant changes to its independent directorship. Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee have been recommended for appointment as Independent Directors for a term of five consecutive years, effective July 02, 2026, subject to shareholder approval. Both incoming directors are unrelated to existing management and are not debarred by SEBI. Concurrently, the Board noted the retirement of Mrs. Aruna Bhinge as an Independent Director, effective from the close of business hours on July 6, 2026, upon completion of her second term. Dr. Mande brings expertise as a structural and computational biologist and was formerly Director General of CSIR.